Get the Stockscreener App
2.09
1.88%
-0.04
Lexaria Bioscience Corp Stock (LEXX) Latest News
Form DEF 14A Lexaria Bioscience Corp. For: Jan 14 - StreetInsider.com
Lexaria Bioscience Corp. (LEXX) reports earnings - Quartz
Lexaria: GLP-1 Drugs Expand Beyond Weight Loss Into Major Disease Treatments | LEXX Stock News - StockTitan
Lexaria Bioscience holds buy rating, steady stock target on positive study results - Investing.com Canada
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled - ACN Newswire
Lexaria Bioscience’s DehydraTECH Outshines in Diabetes Study - TipRanks
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study - Yahoo Finance
LEXXWLexaria Bioscience Corp. Warrant Latest Stock News & Market Updates - StockTitan
Invenomic Capital Management LP Adjusts Stake in Lexaria Bioscie - GuruFocus.com
Lexaria commences unique drug distribution study - Investing.com
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study - WICZ
LEXXLexaria Bioscience Corp. Latest Stock News & Market Updates - StockTitan
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss - Yahoo Finance
Lexaria's DehydraTECH Diabetes Study Advances: FDA-Track Phase 1b Trial Gets Key Approval | LEXX Stock News - StockTitan
Lexaria Bioscience Corp. (LEXX) Quarterly 10-Q Report - Quartzy
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments - Yahoo Finance
Lexaria Positions DehydraTECH Platform in Booming $471B GLP-1 Drug Market | LEXX Stock News - StockTitan
Lexaria reports promising blood sugar control in animal study - Investing.com India
Lexaria reports promising blood sugar control in animal study By Investing.com - Investing.com Australia
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study - StockTitan
Lexaria reports advances in weight loss drug study - Investing.com India
Lexaria reports advances in weight loss drug study By Investing.com - Investing.com UK
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study - StockTitan
Lexaria Bioscience : Corporate Presentation - Marketscreener.com
Lexaria Bioscience Corp. sets date for combined annual and special meeting - Investing.com India
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - ACN Newswire
Lexaria Bioscience : Registered Direct Offering Form 8 K - Marketscreener.com
Companies Like Lexaria Bioscience (NASDAQ:LEXX) Are In A Position To Invest In Growth - Yahoo Finance
Lexaria Bioscience announces $5M securities offering - MSN
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - StockTitan
Lexaria to test DehydraTECH GLP-1 product for weight loss, diabetes - MSN
Lexaria starts pilot study for oral diabetes treatment By Investing.com - Investing.com South Africa
Lexaria starts pilot study for oral diabetes treatment - Investing.com
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing - StockTitan
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing | LEXX Stock News - StockTitan
Lexaria Foresees Lead in Booming GLP-1 Market - TipRanks
Lexaria Updates Current GLP-1 Market - Yahoo Finance
Why Lexaria Bioscience (LEXX) Shares Are Moving - MSN
Lexaria Bioscience appoints new CFO Michael Shankman - Investing.com
Lexaria Bioscience appoints new CFO Michael Shankman By Investing.com - Investing.com Canada
Lexaria Bioscience appoints new CFO amid growth plans By Investing.com - Investing.com Australia
Lexaria Bioscience appoints new CFO amid growth plans - Investing.com
Lexaria Bioscience Welcomes New CFO Amid Growth - TipRanks
Lexaria Bioscience Corp. Appoints Michael Shankman as Chief Financial Officer - Marketscreener.com
Lexaria Advances Oral Diabetes Treatment Study - TipRanks
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 - StockTitan
Stocks of Lexicon Pharmaceuticals Inc (LXRX) are poised to climb above their peers - SETE News
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):